Hutchmed (China) Limited

Transaction in Own Shares • Feb 28, 2024

National Storage Mechanism | Additional information

RNS Number : 8176E

Hutchmed (China) Limited

28 February 2024

Press Release

Publication of Form 20-F

Hong Kong, Shanghai & Florham Park, NJ: Wednesday, February 28, 2024: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today published the Form 20-F for the financial year ended December 31, 2023.  This is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/8176E_1-2024-2-28.pdf and also on the website of the Company at www.hutch-med.com.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

CONTACTS

##### Investor Enquiries	+852 2121 8200 / [email protected]
##### Media Enquiries
Ben Atwell / Alex Shaw, FTI Consulting	+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) / [email protected]
Zhou Yi, Brunswick	+852 9783 6894 (Mobile) / [email protected]
##### Nominated Advisor
Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure Gordon	+44 (20) 7886 2500

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAQKFBNBBKDBBB